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Abstract
Background: Change of Kenyan treatment policy for uncomplicated malaria from sulphadoxine-pyrimethamine to
artemether-lumefantrine (AL) was accompanied by revised recommendations promoting presumptive malaria
diagnosis in young children and, wherever possible, parasitological diagnosis and adherence to test results in older
children and adults. Three years after the policy implementation, health workers’ adherence to malaria diagnosis
and treatment recommendations was evaluated.
Methods: A national cross-sectional, cluster sample survey was undertaken at public health facilities. Data were
collected using quality-of-care assessment methods. Analysis was restricted to facilities with AL in stock. Main
outcomes were diagnosis and treatment practices for febrile outpatients stratified by age, availability of diagnostics,
use of malaria diagnostic tests, and test result.
Results: The analysis included 1,096 febrile patients (567 aged <5 years and 529 aged ≥5 years) at 88 facilities with
malaria diagnostics, and 880 febrile patients (407 aged <5 years and 473 aged ≥5 years) at 71 facilities without
malaria diagnostic capacity. At all facilities, 19.8% of young children and 28.7% of patients aged ≥5 years were
tested, while at facilities with diagnostics, 33.5% and 53.7% were respectively tested in each age group. Overall, AL
was prescribed for 63.6% of children aged <5 years and for 65.0% of patients aged ≥5 years, while amodiaquine or
sulphadoxine-pyrimethamine monotherapies were prescribed for only 2.0% of children and 3.9% of older children
and adults. In children aged <5 years, AL was prescribed for 74.7% of test positive, 40.4% of test negative and
60.7% of patients without test performed. In patients aged ≥5 years, AL was prescribed for 86.7% of test positive,
32.8% of test negative and 58.0% of patients without test performed. At least one anti-malarial treatment was
prescribed for 56.6% of children and 50.4% of patients aged ≥5 years with a negative test result.
Conclusions: Overall, malaria testing rates were low and, despite different age-specific recommendations, only
moderate differences in testing rates between the two age groups were observed at facilities with available diagnostics.
In both age groups, AL use prevailed, and prior ineffective anti-malarial treatments were nearly non-existent. The large
majority of test positive patients were treated with recommended AL; however, anti-malarial treatments for test negative
patients were widespread, with AL being the dominant choice. Recent change of diagnostic policy to universal testing in
Kenya is an opportunity to improve upon the quality of malaria case management. This will be, however, dependent
upon the delivery of a comprehensive case management package including large scale deployment of diagnostics,
good quality of training, post-training follow-up, structured supervisory visits, and more intense monitoring.
Background
Health workers’ adherence to diagnostic and treatment
guidelines is one of the critical aspects determining effec-
tive implementation of malaria case management policies
[1]. In line with international recommendations [2], in
2004 the first-line treatment policy for uncomplicated
malaria in Kenya was changed from ineffective sulpha-
doxine-pyrimethamine (SP) [3] to artemisinin-based
combination therapy (ACT). A specific ACT - arte-
mether-lumefantrine (AL) - was recommended for
patients weighing 5 kg and above, quinine was recom-
mended for children below 5 kg and pregnant women,
SP was reserved for intermittent preventive treatment in
pregnancy (IPTp), and amodiaquine (AQ), a prior and
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failing second-line option [4], was no longer recom-
mended for malaria treatment. To support the change of
treatment policy, malaria diagnostic policies were also
revised to promote presumptive treatment of fever in
children under five years of age and, wherever available,
microscopy or rapid diagnostic tests (RDT) were recom-
mended for testing febrile patients aged five years and
older, with subsequent treatment of only test positive
cases with AL [5].
By the end of 2006, the new treatment policy was
implemented countrywide [6]. Regarding malaria diag-
nostics, health workers were trained on the use of RDTs
during the in-service case management training; how-
ever, only limited quantities of RDTs were supplied, and
most of the malaria diagnostic capacities in the country
relied on the availability of malaria microscopy [7]. The
findings from several studies [8-10] evaluating health
workers’ adherence to age-specific guidelines during the
early AL implementation phase have revealed that: 1)
overall AL use was low in both age groups, with
prevailing practice of prescribing non-recommended
AQ, SP and their combinations; 2) parasitological
diagnosis was underused in older children and adults
while at variance with diagnostic recommendations, a
substantial proportion of young children was tested; 3)
prescriptions of AL largely followed test results and
recommendations - however, most test negative patients
were still treated for malaria, mainly with alternative
and non-recommended treatments.
Between 2007 and 2009, the Kenyan Division of
Malaria Control reinforced health workers’ case manage-
ment practices to adhere to case management guide-
lines. In this paper, malaria diagnosis and treatment
practices observed during the national malaria case
management survey undertaken in 2010 are reported,
approximately three years after the new AL policy was
implemented countrywide.
Methods
Survey design and data collection
A cross-sectional, cluster sample, health facility survey
was undertaken in public facilities between 18th January
and 12th February 2010. From the universe of 6,094
public facilities in Kenya the following categories of
facilities were excluded from the sampling frame: 1)
facilities from Nairobi province due to absence of
malaria transmission and requiring special studies to
evaluate malaria case management, 2) tertiary hospitals
since they serve mainly as referral facilities, and 3) facil-
ities run by other than Ministry of Health (MoH) and
Local Authorities (LA) because they provide services to
special patient groups such as military or prisoners. In
total, 861 facilities were excluded and therefore our
sampling frame consisted of 5,233 health facilities. For
the purpose of sampling, facilities belonging to the faith-
based and non-governmental organizations were classi-
fied into one category. Similarly, MOH and LA owned
facilities were grouped into government category as well
as smaller facilities such as dispensaries and health cen-
tres which also represented one category. Therefore, in
each of seven provinces, four strata based on the facility
type (hospitals versus smaller facilities) and ownership
(government versus faith based/non-government) were
formed. Finally, from each of the 28 strata, a simple,
random sample proportional to the number of facilities
in a stratum was drawn. A cluster was defined as all
outpatient encounters between health workers and
patients occurring on a survey day.
Data at each facility were collected over a single sur-
vey day using a range of quality-of-care methods includ-
ing health facility assessments, health worker interviews,
and exit interviews with caretakers and patients. Firstly,
all patients presenting to the outpatient departments
underwent rapid screening when they were ready to
leave the facility. Non-referred and non-pregnant
patients weighing 5 kg and above and presenting for an
initial outpatient visit with fever underwent a detailed
interview. Of relevance for this report, the information
about patients’ age, weight, temperature, main com-
plaints, routine malaria diagnostics requested, results
reported and medications prescribed was collected dur-
ing the exit interview and from the patient-held cards.
Secondly, each facility was assessed to determine the
survey day availability of anti-malarial drugs, antibiotics,
malaria RDTs and functional malaria microscopy ser-
vice. Finally, at the end of the working day, all health
workers who saw recruited patients on the survey day
were interviewed to collect information on their demo-
graphics and exposure to malaria case management
interventions. Informed written consent was obtained
for all participants.
Definitions and analytical approaches
The study definitions reflected national guidelines for
management of uncomplicated malaria, which were
valid at the time of the study [11]. In summary, the
guidelines recommend that in high malaria risk areas,
all children under five years of age with fever or history
of fever should be presumptively treated with AL. In
low malaria risk areas, presumptive treatment with AL
is recommended in all febrile children in the absence of
measles, runny nose and other obvious causes of fever.
For clinical management purposes, all parts of Kenya
were classified as high malaria risk areas, except the
highlands of Central and Nairobi provinces. In patients
aged five years and older and regardless of the malaria
risk, all febrile patients in the absence of another
obvious cause of fever should be tested for malaria
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(microscopy or RDT) and only test positive patients
should be treated with AL. In the same age group, pre-
sumptive AL treatment is recommended in absence of
malaria diagnostics.
Therefore, to reflect criteria for testing and AL treat-
ment, all analyses were restricted to febrile, non-
pregnant patients weighing 5 kg and above, presenting
for an initial outpatient visit without being referred or
admitted for hospitalization. Patients aged five years and
older presenting with another obvious cause of fever, as
well as the children less than five years of age meeting
the same criteria in low risk areas, were excluded from
the analysis. Another obvious cause of fever was defined
as febrile patients presenting concomitantly with runny
nose, sore throat, oral thrush, wounds, urinary problem,
skin problem or abscesses. Fever was defined as axillary
temperature of ≥37.5°C or a history of fever during the
present illness.
To ensure comparable evaluation of anti-malarial
treatment practices based on different age-specific
recommendations for malaria diagnosis, the focus of the
analysis was observations from health facilities where
AL was in stock during the survey, stratified by the
availability of diagnostics and patients’ age (under five
and over five years of age). At facilities with malaria
diagnostics, anti-malarial treatment practices were
further stratified by the use of malaria diagnostic tests
and the patient’s test result. Combined microscopy and
RDT results are presented since the small number of
patients with malaria RDTs precluded a meaningful ana-
lysis stratified by type of diagnostics.
Data entry and management was undertaken using
Access (Microsoft, USA), through customized data entry
screens with in-built range and consistency checks. All
forms were entered twice by independent data entry
clerks and data files were compared for errors using a
verification programme and referring to original ques-
tionnaires. All analyses were performed using STATA,
version 11. The precision of proportions (95% confi-
dence interval [CI]) was determined adjusting for the
cluster sampling at the health facility level.
Ethical approval
Ethical approval for the survey was provided by the
Kenyatta National Hospital/University of Nairobi-Ethics
& Research Committee (reference number KNH-ERC/
A/383).
Results
Sample description
The survey was undertaken at 174 public health facil-
ities, of which the majority (70.1%) were government
facilities, followed by faith-based (25.9%) and non-
governmental organization facilities (1.2%). Most
facilities were dispensaries (70.1%), while health centres
and hospitals accounted for 18.4% and 11.5% of facil-
ities, respectively. Parasitological diagnosis of malaria
was available on the survey day at 96 (55.2%) facilities,
more commonly using malaria microscopy (88/96;
91.7%) than RDTs (13/96; 13.5%). Five health facilities
had both diagnostic capacities. AL was available in
94.3% facilities, while SP tablets, quinine injections and
quinine tablets were respectively in stock at 88.5%,
77.6% and 69.0% of facilities. Non-recommended AQ
was available in only 23.6% of facilities.
Malaria diagnosis and treatment practices were ana-
lysed for 1,976 febrile patients who met the inclusion
criteria (974 aged <5 years and 1,002 aged ≥5 years), at
159 facilities where AL was in stock on the survey day.
At five facilities with AL in stock, no febrile patients
meeting the inclusion criteria were seen during the sur-
vey days. Of these 1,976 febrile patients, 1,096 (567 aged
<5 years and 529 aged ≥5 years) were seen at 88 facil-
ities with malaria diagnostic support. The remaining 880
patients (407 aged <5 years and 473 aged ≥5 years) were
seen at 71 facilities without malaria diagnostic capacity.
Malaria testing and routine test positivity rates
Table 1 presents age-specific malaria testing rates for
1,976 febrile patients seen at all study facilities and
1,096 patients seen at facilities with malaria diagnostic
support. At all facilities, 24.3% (95% CI: 19.0-29.7) of
febrile patients were tested. At facilities with malaria
diagnostic support, 43.2% (95% CI: 36.4-50.1) were
tested. Among patients aged ≥5 years, 53.7% (95% CI:
45.4-61.9) of older children and adults were tested at
facilities with diagnostic support. Interestingly, at the
same facilities, 33.5% (95% CI: 25.1-42.0) of children
<5 years of age had also undergone parasitological
testing. Among tested patients, the routine malaria
test positivity rate was 54.0% (95% CI: 45.4-62.6), with
the proportion higher, although not statistically signifi-
cant, in older children and adults (58.1%; 95%: 46.9-
69.3) than in children <5 years of age (47.9%; 95% CI:
38.3-57.5).
Anti-malarial treatment practices for febrile children
under five years of age
Table 2 presents anti-malarial treatment practices for
febrile children <5 years of age stratified by the availabil-
ity of diagnostics, use and result of malaria test. Overall,
the large majority of febrile children were treated with
recommended AL (63.6%; 95% CI: 58.5-68.6); 9% (95%
CI: 5.8-12.1) were treated with non-recommended qui-
nine or combination of AL and quinine (AL+QN); only
2% (95% CI: 0.5-3.6) received ineffective AQ or SP
monotherapies; 25.4% (95% CI: 20.9-29.8) were not trea-
ted for malaria.
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Among test positive children, anti-malarial treatment
was prescribed universally and 74.7% (95% CI: 61.0-88.5)
of children were treated with AL, 18.7% (95% CI: 6.5-
30.9) with AL+QN and 5.5% (95% CI: 0.8-10.2) with
quinine alone. Notably, none of the test positive chil-
dren were treated with ineffective AQ or SP monothera-
pies (Table 2). Interestingly, among test negative
children, AL was prescribed for 40.4% (95% CI: 26.6-
54.3) of these children, 9.1% (95% CI: 2.5-15.7) were
treated with AL+QN or quinine alone and 7.1% (95%
CI: 0-15.4) were treated with either AQ or SP mono-
therapies. At least one anti-malarial drug was prescribed
for 56.6% (95% CI: 43.1-70.0) of the test negative chil-
dren. AL treatment also prevailed among children with-
out test performed at facilities with (60.7%; 95% CI:
51.2-70.3) and without (69.3%; 95% CI: 62.1-76.5) diag-
nostic support. Finally, across all patient categories, over
75% of children were treated with antibiotics (Table 2).
Anti-malarial treatment practices for febrile patients aged
five years and older
Table 3 presents anti-malarial treatment practices for
febrile patients aged five years and older stratified by the
availability of diagnostics, use and result of malaria test.
Across all patient categories, the patterns of anti-
malarial treatments observed in this age group were
similar to those observed in children under five years
of age. In summary, nearly two thirds of all patients
were treated with AL (65.0%; 95% CI: 59.8-70.1), treat-
ments with ineffective AQ or SP monotherapies were
very rare (3.9%; 95% CI: 1.7-6.1), at least one anti-
malarial drug was prescribed for half of the test nega-
tive patients (50.4%; 95% CI: 38.6-62.3), AL was treat-
ment of choice for test positive patients (86.7%; 95%
CI: 79.8-93.5) but also commonly used for patients
with negative test (32.8%; 95% CI: 20.6-44.9), and those
without test performed at facilities with (58.0%; 95% CI:
46.6-69.3) and without (69.1%; 95% CI: 61.7-76.5) diag-
nostic support. 68.9% (95% CI: 64.8-73.0) of patients
were treated with antibiotics, yet at variance to children
under five years of age, the non-recommended AL+QN
treatment was less common for test positive patients
(7.3%; 95% CI: 2.1-12.4).
Discussion
Adherence to testing recommendations
Between 2006 and 2009, Kenya promoted malaria diag-
nostic policy recommending parasitological testing for
Table 1 Malaria testing rates for febrile patients under and over 5 years of age
All health facilities Aged < 5 years
(N = 974)
Aged ≥ 5 years
(N = 1,002)
All age groups
(N = 1,976)
n (%) 95% CI n (%) 95% CI n (%) 95% CI
Tested for malaria 193 (19.8) 14.3-25.3 288 (28.7) 21.8-35.7 481 (24.3) 19.0-29.7
Health facilities with malaria diagnostics < 5 years
(N = 567)
≥ 5 years
(N = 529)
All age groups
(N = 1,096)
n (%) 95% CI n (%) 95% CI n (%) 95% CI
Tested for malaria 190 (33.5) 25.1-42.0 284 (53.7) 45.4-61.9 474 (43.2) 36.4-50.1
Table 2 Anti-malarial treatment practices for febrile children under 5 years of age stratified by the availability of
diagnostics, use and result of malaria test
Children aged < 5 years Health facilities with diagnostics Health facilities without diagnostics All health facilities
Positive
test
N = 91 (%)
Negative
test
N = 99 (%)
Test
not done
N = 377 (%)
All children
N = 407 (%)
Total
N = 974 (%)
AL 68 (74.7) 40 (40.4) 229 (60.7) 282 (69.3) 619 (63.6)
AL+QN 17 (18.7) 6 (6.1) 22 (5.8) 16 (4.0) 61 (6.3)*
QN 5 (5.5) 3 (3.0) 10 (2.7) 8 (2.0) 26 (2.7)
SP 0 5 (5.1) 8 (2.1) 1 (0.3) 14 (1.4)
AQ 0 2 (2.0) 4 (1.1) 0 6 (0.6)
QN+SP 1 (1.1) 0 0 0 1 (0.1)
No AM prescribed 0 43 (43.4) 104 (27.6) 100 (24.6) 247 (25.4)
Any AM prescribed 91 (100) 56 (56.6) 273 (72.4) 307 (75.4) 727 (74.6)
Antibiotic prescribed 70 (76.9) 89 (89.9) 281 (74.5) 329 (80.8) 769 (79.0)
*All QN treatments as part of AL+QN therapy include administration of injectable quinine
AL, artemether-lumefantrine; AQ, amodiaquine; SP, sulphadoxine-pyrimethamine; QN, quinine; AM, anti-malarial.
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febrile older children and adults and presumptive diag-
nosis in young children. The findings from this 2010
study revealed low testing rates without substantial dif-
ference between children under five years of age (20%)
and older children and adults (29%). While the absence
of malaria diagnostics in nearly half of the facilities due
to partial deployment of RDTs provides an explanation
for low testing rates in older children and adults, the
testing practices observed at facilities with available
diagnostics are worth noting. At these facilities, despite
the increase in testing rates compared with all facilities,
the testing rates for febrile older children and adults did
not exceed 54%, and at variance with presumptive
recommendations for children under 5 years of age, 34%
of these children were still tested. The testing patterns
found in this study concur with reports from studies
undertaken during the early AL implementation in
Kenya, which suggested underuse of testing in older
children and adults and important presence of testing in
children under five years of age [9].
The in-service malaria case management training for
health workers - the key implementation activity reinfor-
cing age-specific recommendations for malaria testing
between 2007 and 2009 - deserves special attention. The
issues related to the quality of in-service training and
unclear or incorrect case management messages com-
municated to health workers during the early AL imple-
mentation phase in 2006 were previously reported [12].
Despite the standardization of the training between
2007 and 2009 through the development of the unique
curriculum [13], it should be acknowledged that the
large scale, multi-cascade training programme covering
more than 20,000 health workers in over 500 training
sessions and implemented by 15 different organizations
is unlikely to be sufficient to guarantee uniformed qual-
ity of training and to result in changes of practices if it
is not supported with post-training follow-up and struc-
tured supportive supervision. Unfortunately, the last
components were the weakest parts of the case manage-
ment activities, which were rarely present throughout
the process of the policy implementation.
Nevertheless, in 2010, Kenya has changed diagnostic
policy and case management guidelines to unambigu-
ously recommend parasitological testing of all febrile
patients regardless of the age category [14]. Therefore,
more positively, non-adherent practices in young chil-
dren as suggested in this study can be viewed as a posi-
tive starting point under the new policy. Currently, at
facilities with available diagnostics, only 43% of all feb-
rile patients are tested, yet when compared with results
reported in similar studies, this is more common than
the 40% of patients tested in Uganda [15], 31% in
Angola [16], 27% in Zambia [17] and 27% in Tanzania
[18]. After the policy and guidelines recommendations
have abandoned presumptive diagnosis in young chil-
dren in Kenya, it is believed that future implementation
of a comprehensive case management package based on
large scale deployment of RDTs with emphasis on post-
training follow up and structured supervisory activities
would further increase health workers adherence to new
testing recommendations.
Change in treatment practices from ineffective anti-
malarial therapies to AL
The findings of this analysis, three years after AL was
delivered to health facilities in Kenya, have shown that
AL treatment practices have prevailed over other anti-
malarial treatments in both age groups (64% in young
Table 3 Anti-malarial treatment practices for febrile patients 5 years and older stratified by the availability of
diagnostics, use and result of malaria test
Patients aged ≥ 5 years Health facilities with diagnostics Health facilities without diagnostics All health facilities
Positive
test
N = 165 (%)
Negative
test
N = 119 (%)
Test
not done
N = 245 (%)
All patients
N = 473 (%)
Total
N = 1,002 (%)
AL 143 (86.7) 39 (32.8) 142 (58.0) 327 (69.1) 651 (65.0)
SP 1 (0.6) 16 (13.5) 9 (3.7) 12 (2.5) 38 (3.8)
AL+QN 12 (7.3) 2 (1.7) 0 16 (3.4) 30 (3.0)*
QN 6 (3.6) 2 (1.7) 1 (0.4) 7 (1.5) 16 (1.6)
AQ 0 1 (0.8) 0 0 1 (0.1)
Other AM 1 (0.6) 0 1 (0.4) 2 (0.4) 4 (0.4) †
No AM prescribed 2 (1.2) 59 (49.6) 92 (37.6) 109 (23.0) 262 (26.2)
Any AM prescribed 163 (98.8) 60 (50.4) 153 (62.5) 364 (77.0) 740 (73.9)
Antibiotic prescribed 90 (54.6) 92 (82.4) 169 (69.0) 333 (70.4) 690 (68.9)
*All QN treatments include administration of injectable quinine
† Other anti-malarial treatment included dihydroartemisinin (2), QN+SP (1) and AL+SP (1).
AL, artemether-lumefantrine; AQ, amodiaquine; SP, sulphadoxine-pyrimethamine; QN, quinine; AM, anti-malarial.
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children and 65% in older children and adults). Despite
non-adherent practices that are still present, it is impor-
tant to note that the use of ineffective monotherapies
such as SP or AQ was nearly non-existent. However,
the use of the non-recommended combination of AL
and quinine was particularly common among test posi-
tive children under five years of age (18%). These find-
ings reveal a major shift in treatment practices
compared with reports during the early AL implementa-
tion, which were characterized by low AL use in both
age groups, with prevailing practice of prescribing non-
recommended AQ, SP and their combinations [8-10].
There are several possible explanations for these pat-
terns. Firstly, despite the change of policies and deploy-
ment of AL to peripheral facilities, the discontinuation
of old treatment practices and the translation of new
policies into recommended clinical practice is a rela-
tively slow process. The slow changes in treatment prac-
tices observed during the early and late implementation
process in Zambia [19] concur with this view. Secondly,
declining availability of non-recommended AQ at Ken-
yan facilities is likely to be a further determinant pre-
venting health workers’ selection of ineffective
treatments. In prior studies the similar findings were
suggested with respect to the availability of chloroquine
in Uganda under the ACT policy [20] and indeed in
Kenya during the prior SP policy [21]. Thirdly, incorrect
training messages on adequate AQ efficacy and its
potential role in case management that were initially
delivered to health workers during the early implemen-
tation phase [12] were corrected over time. Finally, with
respect to the emergence of AL+QN use in test positive
patients, the prior studies in Kenya have frequently
shown that patients presenting with conditions that are
more likely to be malaria are more commonly treated
with second-line treatments or drugs perceived by
health workers to be a “stronger” cure for malaria
[12,22]. Furthermore, since this pattern is prominent in
young children where vomiting complaints are common,
the use of intramuscular quinine in combination with
AL might be explained as the health worker’s treatment
strategy for reducing the risk of the patient’s non-adher-
ence. Yet this is the practice that should be discouraged,
and among patients with non-severe febrile disease,
emphasis should be put on oral AL treatments with the
first dose administered at the facility under direct
observation.
Challenges in adherence to test negative results
Anti-malarial treatment practices for test negative
patients deserve special attention since failure to adhere
to test negative results severely compromises the cost-
benefit of testing-based malaria case management strate-
gies [23]. These findings revealed that as high as 58% of
test negative young children and 50% of older children
and adults are treated for malaria. In both age groups,
the dominant treatment for test negative patients was
AL. The prior reports from Kenya during the early
implementation phase suggested that AL prescriptions
largely followed test results [9] while alternative anti-
malarial treatments were reserved for test negative
patients. In this study, it was observed that the initial
encouraging observations of most AL treatments adher-
ing to the test negative results were reversed three years
later when the overwhelming majority of treated test
negative patients were indeed treated with AL.
There are several possible explanations for these pat-
terns in this study. While in young children, the disre-
gard of test negative patients could be explained by the
promotion of presumptive treatment (but without test-
ing) during the study period, the magnitude of practices
in discordance with implemented guidelines is worrying
in older children and adults. Reduced availability of
non-recommended AQ in public health facilities has not
resulted in more rational use of anti-malarial drugs for
test negative patients but alongside more established AL
policy in switch of practices from AQ to AL. However,
non-adherence to test-negative results is not unique to
Kenya, and larger scale evaluations have often reported
similar results across Africa under the microscopy-based
[18,24,25] and RDT-based [16,17,26] diagnostic strate-
gies. Conversely, smaller scale studies undertaken under
more controlled conditions have suggested that more
intensive interventions, including integrated in-service
training supported with supervision and strengthened
monitoring and surveillance, may improve adherence to
test results [27-30]. An important component to support
health workers in the management of test negative
patients is development and implementation of guide-
lines for management of non-malaria febrile illness. This
component has not been addressed in 2010 in Kenya,
and the opportunity lies in the forthcoming large-scale
implementation of RDTs. Finally, it was observed that
respectively 90% and 82% of test negative young chil-
dren and patients five years and older were treated with
antibiotics. More pragmatically, if prescriptions of medi-
cations are perceived as good quality of care, then the
withdrawal of anti-malarial treatment for test negative
patients would not substantially interfere with this per-
ception. In most cases, the main difference would be
only an omission of anti-malarial treatment from the
existing polypharmacy prescriptions. Further qualitative
research is required to better understand these practices.
Conclusions
Overall, malaria testing rates were low and despite dif-
ferent recommendations for malaria diagnosis for
patients under and over five years of age, only moderate
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differences in testing rates between the two age groups
were observed at facilities where diagnostics were avail-
able. More positively, in both age groups, AL treatment
practices have prevailed over other anti-malarial treat-
ments and the use of ineffective monotherapies was
nearly non-existent. Furthermore, the large majority of
test positive patients were treated with recommended
AL, while in the smaller subset of non-adherent treat-
ments the use of AL+QN was observed. However, the
use of anti-malarials for test negative patients was wide-
spread, with AL being the dominant treatment choice.
Further improvements in malaria case management are
urgently required and they will be dependent upon the
delivery of a comprehensive case management package
including deployment of RDTs, good quality training,
post-training follow-up, structured supervisory visits,
and more intense monitoring. The recent change of
diagnostic policy abandoning presumptive treatment and
recommending universal parasitological diagnosis across
all age groups should be an opportunity to strengthen
the quality of malaria case management.
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